Department of Pharmaceutical Sciences, I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.
Assay Drug Dev Technol. 2024 Jan;22(1):1-17. doi: 10.1089/adt.2023.059. Epub 2023 Dec 29.
The objective of this study was to develop and evaluate a novel vesicular formulation of luliconazole (LUL) for the management of infection through a topical route. LUL-loaded transethosomes (LUL-TE) were prepared by the film hydration method and various independent and dependent variables were optimized using the Box-Behnken design. Selected critical material attributes were the content of phospholipids (X1), concentration of ethanol (X2), and amount of sodium cholate (X3). Formulated LUL-TE were characterized for percent entrapment efficiency, percent drug loading, vesicle size, and polydispersity index (PDI) and were incorporated into the carbomer gel base and further evaluated for gel characterizations. The prepared transethosomal gel (LUL-TE-CHG) was evaluated for pH, spreadability, viscosity, antifungal activity, and study. From the observed results, it was evident that the prepared LUL-TE-CHG was in the desired pH (6.2 ± 0.45), spreadability [8.3 ± 0.42 g/(cm·s)], viscosity (236.1-19.2.26 mPa·s), nanovesicle size (252 ± 9.82), entrapment efficiency (85% ± 5.24%), zeta potential (-34.05 ± 3.52 mV), and PDI (0.233 ± 0.002). The zone of inhibition results suggested that the LUL-TE-CHG formulation has the highest antifungal activity, that is, 5.83 ± 0.15 mm. The results showed that drug release within 2 h was 18.1% ± 2.0% and after that sustained release action, 83.2% ± 1.7% within 8 h. Finally, to confirm the therapeutic efficacy of the developed formulation, fungal infection was induced by using C. albicans in Wistar rats. , skin irritation study and histopathology studies were performed in the disease-induced model. Animal experiments revealed that LUL-TE-CHG has significantly improved the diseased condition in Wistar rats. The results observed from the skin permeation and skin deposition profile ensure that the prepared novel LUL-loaded TE system had a higher permeation rate and increased retention time compared with LUL-CHG. The hydrogel incorporated with LUL could be a novel approach with safe and effective fungal treatment.
本研究旨在开发和评估一种新型的卢立康唑(LUL)囊泡制剂,通过局部途径治疗感染。通过薄膜水化法制备载卢立康唑的transethosomes(LUL-TE),并使用 Box-Behnken 设计优化各种独立和依赖变量。选择关键的材料属性为磷脂含量(X1)、乙醇浓度(X2)和胆酸钠用量(X3)。对包封率、载药量、囊泡大小和多分散指数(PDI)进行表征,并将其掺入卡波姆凝胶基质中,进一步评估凝胶特性。制备的 transethosomal 凝胶(LUL-TE-CHG)进行 pH 值、铺展性、粘度、抗真菌活性和体内研究评价。从观察结果来看,制备的 LUL-TE-CHG 的 pH 值(6.2±0.45)、铺展性[8.3±0.42 g/(cm·s)]、粘度(236.1-19.2.26 mPa·s)、纳米囊泡大小(252±9.82nm)、包封率(85%±5.24%)、Zeta 电位(-34.05±3.52 mV)和 PDI(0.233±0.002)均在理想范围内。抑菌圈结果表明,LUL-TE-CHG 制剂具有最高的抗真菌活性,即 5.83±0.15mm。结果表明,2 小时内药物释放 18.1%±2.0%,8 小时后持续释放 83.2%±1.7%。最后,为了验证所开发制剂的治疗效果,采用白色念珠菌在 Wistar 大鼠中诱导真菌感染。进行了皮肤刺激性研究和疾病诱导模型中的组织病理学研究。动物实验表明,LUL-TE-CHG 显著改善了 Wistar 大鼠的病情。从皮肤渗透和皮肤沉积曲线观察到的结果表明,与 LUL-CHG 相比,制备的新型 LUL 载药 TE 系统具有更高的渗透速率和更长的滞留时间。含有 LUL 的水凝胶可能是一种安全有效的真菌治疗的新方法。